|  |  | 

India Top Headlines

Moderna’s single dose Covid-19 vaccine in India probably next year; Pfizer ready with 5 crore doses by 2021 | India News


NEW DELHI: Moderna expects to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other Indian companies, while another American giant, Pfizer, is set to offer Rs.5 million injections in 2021, but wants a significant amount. Regulatory relaxations, including severance pay, sources said Tuesday.
While Moderna has conveyed to Indian authorities that it has no vaccine surpluses to share in 2021, there are limited prospects for Johnson & Johnson to export its injections from the US to other countries in the near future, the sources familiar with the matter added. the discussions.
Two rounds of high-level meetings chaired by the Cabinet Secretary on the availability of vaccines in the global and domestic market were held last week, as it was felt that there is an urgent need to obtain the jabs at a time when the country is reeling. under an unprecedented second wave of Covid-19 and a widening gap between supply and requirements.
The country is currently using two ‘made in India’ jabs, Covishield and Covaxin, to inoculate its population of over 1 billion and has administered 20 crore doses since launching the world’s largest vaccination campaign in mid-January. . A third vaccine, Russian-made Sputnik V, has been approved by the government and is currently being used on a smaller scale.
Officials from the Ministry of Foreign Affairs, NITI Aayog, the Department of Biotechnology, the Ministry of Justice and the Ministry of Health were present at the high-level meeting.
It was discussed that Moderna has no vaccine surpluses to share in 2021 and that it plans to launch its single dose vaccine for the Indian market only in 2022, for which, they are in discussion with Cipla and other Indian companies, a source. saying.
Cipla is known to have already shown interest in acquiring 5 crore doses of Moderna by 2022 and has requested confirmation from the central government regarding stability in regulatory requirements / policy regime. The Ministry of Health has also been asked to make an advance decision on Cipla’s request regarding the support required by them for the procurement of Moderna vaccines.
In the case of Pfizer, the US pharmaceutical giant has indicated the availability of vaccine doses of 5 crore (1 crore in July, 1 crore in August, 2 crore in September and 1 crore in October) for supply to India in 2021 and that it will negotiate only with the Indian government and the payment of the vaccines will have to be made by the Center to Pfizer India.
The central government will make its own arrangements for a greater channeling of vaccines purchased in the domestic market.
According to another source, for the supply of vaccines to India, Pfizer has requested compensation from the Indian government and a document has been received in this regard from Pfizer Inc.
In addition, Pfizer has also pursued certain relaxations in the regulatory regime, including relaxation in the requirement for post-approval bridge trials and the dispensing of the requirement to test its vaccines at CDL (Central Drug Laboratory).
Taking into account the company’s track record, similar agreements made with other countries in the world, and the current pandemic situation, the government can take an overview to compensate the company, the officials said, but noted that in case an opinion is adopted To compensate the company, other companies may file similar lawsuits.
According to information provided by Pfizer, about 116 countries in the world, including the US, have signed the indemnity document.
In addition, considering that more than 14.7 crore of Pfizer doses had been administered worldwide without any significant reports of adverse effects, it is necessary to take the position of indemnifying the company to supplement the availability of vaccines in India. officials said at a recent meeting.
It was suggested that a decision can be made on the Pfizer Inc issue as soon as possible and that NEGVAC (National Group of Experts on Vaccine Administration for Covid-19) can hold a meeting immediately on these issues.
At a press conference on Monday, responding to a question about states that cannot procure vaccines directly from Moderna and Pfizer, Deputy Secretary of the Ministry of Health Lav Agarwal said: “Either Pfizer or Moderna, at the level of Center, we have been coordinating with them. ”
“Also, Pfizer and Moderna’s order book is full, so it depends on their surplus how much they can provide in India … they will go back to the Center and we will help in facilitation to the states,” he said.

Original source